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Germline mutations in the putative tumor suppressor gene, BRCA1, predispose women to dramatically elevated risks of breast
cancer, while germline mutations in the structurally unrelated gene, BRCA2, predispose both men and women to breast
cancer. Recent studies have suggested an important developmental role for the murine homologue of BRCA1 in the regulation
of proliferation and differentiation. At the present time, however, little is known about the developmental role of BRCA2 or
the regulation of its expression in vivo. We have determined the spatial and temporal pattern of expression of the murine
homologue of BRCA2 during fetal development, in adult tissues, and in the mammary gland during postnatal development. Our
results indicate that Brca2 mRNA expression is highest in proliferating cellular compartments, particularly those undergoing
differentiation. In the breast, Brca2 expression is developmentally regulated and is induced during puberty and pregnancy and
as a result of parity. Surprisingly, in multiple fetal and adult tissues the spatial and temporal pattern of Brca2 mRNA expression
is virtually indistinguishable from that of Brca1, despite the fact that these genes display no homology. These observations
suggest that Brca2 is involved in the processes of proliferation and differentiation in the mammary gland and other tissues,
and that Brca1 and Brca2 mRNA expression may be regulated by similar pathways and stimuli in multiple cell types.
Interestingly, however, our analysis reveals that Brca1 and Brca2 expression are differentially regulated during the development
of speci®c endocrine target tissues, such as the testis during spermatogenesis and the breast during pregnancy. In addition,
the ratio of mRNA expression in the mammary glands of adult females relative to adult males is signi®cantly greater for Brca1
than for Brca2. These observations imply that Brca1 and Brca2 mRNA expression are differentially regulated by sex hormones.
In order to test this hypothesis, we have analyzed the expression of these two breast cancer susceptibility genes in ovariecto-
mized mice treated with 17b-estradiol and progesterone. Our results demonstrate that the up-regulation of mRNA expression
in the breast by ovarian hormones is signi®cantly greater for Brca1 than for Brca2. These observations suggest that the gender-
speci®c differences in phenotype associated with germline mutations in BRCA2 versus BRCA1 may be related to the differential
regulation of these genes by sex hormones. q 1997 Academic Press
INTRODUCTION connection between carcinogenesis and development is il-
lustrated by the existence of endocrine risk factors for breast
cancer that are related to the timing of normal develop-The loss of growth control characteristic of carcinogene-
mental events such as menarche, menopause, and age atsis is uniformly accompanied by alterations in normal path-
®rst full-term pregnancy. The observation that the sameways of differentiation and development. In the breast, the
reproductive endocrine events which control breast devel-
opment also in¯uence breast cancer risk supports the hy-
pothesis that mammary gland development and mammary1 To whom correspondence and reprint requests should be
gland carcinogenesis are fundamentally related.addressed. Fax: (215) 573-8590. E-mail: chodosh@mail.med.
upenn.edu. The epidemiological relationship between differentiation
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and carcinogenesis is illustrated on a molecular level by the count for a smaller proportion of families with inherited
breast cancer than those associated with BRCA1 (Woosterexistence and function of tumor suppressor genes. Germline
mutations in these genes are associated with inherited can- et al., 1994, 1995; Phelan et al., 1996; Couch et al., 1996b).
In contrast to BRCA1, however, breast cancer incidence iscer predisposition syndromes (Knudson, 1993). Genetic
analysis of families in which multiple individuals have de- markedly increased in men as well as in women inheriting
mutations in BRCA2. Germline mutations in BRCA2 alsoveloped breast cancer suggests that 5±10% of breast cancer
cases result from the inheritance of germline mutations in predispose female carriers to less severely elevated risks of
ovarian cancer than those associated with BRCA1 muta-autosomal dominant susceptibility genes (Claus et al.,
1991; Newman et al., 1988). In late 1994, one of these breast tions (Couch et al., 1996b; Phelan et al., 1996; Tavtigian et
al., 1996; Thorlacius et al., 1995, 1996; Wooster et al., 1994,cancer susceptibility genes, BRCA1, was isolated by posi-
tional cloning (Hall et al., 1990; Miki et al., 1994). Germline 1995). The supposition that BRCA2 is a tumor suppressor
gene is supported by the observation that most breast tu-mutations in this gene appear to account for most families
with inherited breast and ovarian cancer and about half of mors arising in patients with germline BRCA2 mutations
exhibit LOH at the BRCA2 locus, typically involving lossfamilies displaying inherited breast cancer alone (Easton et
al., 1993). Tumors arising in patients with germline BRCA1 of the wild-type BRCA2 allele (Collins et al., 1995; Gud-
mundsson et al., 1995). However, similar to the failure tomutations typically display loss of the wild-type BRCA1
allele, suggesting that BRCA1 is a tumor suppressor gene ®nd BRCA1 mutations in sporadic breast cancers, only a
small percentage of sporadic breast and ovarian tumors ap-(Smith et al., 1992). Taken together with ®ndings that re-
duction in BRCA1 expression in vitro results in accelerated pear to carry somatic mutations in the BRCA2 gene despite
the fact that 25±30% of sporadic breast cancers show LOHgrowth of breast and ovarian cancer cell lines, while overex-
pression of BRCA1 results in inhibited growth of such cell at this locus (Lancaster et al., 1996; Miki et al., 1996; Teng
et al., 1996).lines, these observations are consistent with a model in
which BRCA1 negatively regulates proliferation in adult Breast cancer in men is a rare disease with an incidence
approximately 100 times lower than that found in womentissues (Holt et al., 1996; Rao et al., 1996; Thompson et
al., 1995). Interestingly, however, the murine homologue of (Crichlow, 1972; Meyskens et al., 1976). Several risk factors
for male breast cancer have an underlying endocrine compo-BRCA1 is expressed at highest levels in the mouse in cellu-
lar compartments containing rapidly proliferating cells, par- nent related to decreased ratios of androgens to estrogens
(Meyskens et al., 1976; Thomas et al., 1992). This relation-ticularly those undergoing differentiation, such as in the
breast during puberty and pregnancy (Lane et al., 1995; ship is highlighted by the existence of families with inher-
ited male breast cancer due to mutations in the androgenMarquis et al., 1995). The positive correlation between
Brca1 expression and cellular proliferation may be ex- receptor (Wooster et al., 1992). Since androgen response
pathways are required for normal mammary gland develop-plained in part by the observation that the expression of
this gene is regulated in a cell cycle-dependent fashion, with ment, and since epidemiological evidence suggests that al-
terations in these pathways predispose men to increasedpeak steady-state levels of mRNA and protein occurring at
the G1/S transition (Chen et al., 1996; Gudas et al., 1996; risks of mammary neoplasia, the potential regulation of
BRCA2 expression by steroid hormones is of considerableRajan et al., 1996; Vaughn et al., 1996b). These observa-
tions, together with the ®nding that BRCA1 is a substrate biological interest. That breast cancer incidence is not in-
creased in men inheriting mutations in BRCA1 suggestsfor certain cyclin-dependent kinases, suggest a possible
function for BRCA1 in cell cycle checkpoint control and that the expression and/or function of BRCA1 and BRCA2
may differ in some tissues with respect to hormonal path-the regulation of proliferation (Chen et al., 1996). Consis-
tent with this hypothesis, several groups have now demon- ways involved in the regulation of growth and differentia-
tion.strated that homozygous mutations in Brca1 in mice result
in abnormalities in cellular proliferation as well as early At the present time, little is known about BRCA2 func-
tion or the regulation of its expression. BRCA2 is a largeembryonic lethality (Gowen et al., 1996; Hakem et al.,
1996; Liu et al., 1996). gene from which an approximately 11-kb mRNA is tran-
scribed (Couch et al., 1996a; Tavtigian et al., 1996; WoosterThe existence of the breast cancer susceptibility gene,
BRCA2, was initially suggested by the observation that the et al., 1995). This transcript is predicted to encode a 3418-
amino acid polypeptide showing little or no homology tomajority of breast cancer families with multiple cases of
early-onset disease and at least one affected male are not previously identi®ed proteins (Tavtigian et al., 1996). Like
BRCA1, few somatic mutations in BRCA2 have been identi-linked to BRCA1 (Stratton et al., 1994). The BRCA2 locus
was subsequently mapped by linkage analysis to chromo- ®ed in sporadic breast tumors. Also like BRCA1, the numer-
ous germline mutations that have been identi®ed in BRCA2some 13q12-13 and has recently been isolated by positional
cloning (Tavtigian et al., 1996; Wooster et al., 1994, 1995). are distributed throughout the gene, and the majority of
these mutations result in protein truncation (Couch et al.,Like BRCA1, most women inheriting germline mutations
in BRCA2 have a high probability of developing breast can- 1996b; Neuhausen et al., 1996; Phelan et al., 1996; Tavtig-
ian et al., 1996; Thorlacius et al., 1996; Wooster et al., 1995).cer, although germline mutations in BRCA2 appear to ac-
Copyright q 1997 by Academic Press. All rights of reproduction in any form reserved.
AID DB 8526 / 6x1f$$$$$2 04-08-97 13:50:19 dbas
387Developmental Regulation of Brca2 Expression
bath. Mammary gland harvest consisted in all cases of the numberNevertheless, there are no apparent extended regions of nu-
three, four, and ®ve mammary glands. The lymph node embeddedcleotide or amino acid homology between BRCA1 and
in the number four mammary gland was removed prior to harvest.BRCA2. Recently, we and others have shown that Brca2
The mammary glands from between 10 and 40 age-matched micemRNA expression in vitro is up-regulated in rapidly prolif-
were pooled for each developmental or experimental point.erating cells, is down-regulated in response to serum depri-
For hormonal treatment experiments, adult female FVB mice
vation, and is expressed in a cell cycle-dependent manner were anesthetized and subject to bilateral oophorectomy. Two
peaking at the G1/S boundary (Rajan et al., 1996; Vaughn weeks later, mice began receiving daily subcutaneous injections
et al., 1996a). In addition, our studies indicate that Brca2 with either phosphate-buffered saline (PBS) and gum arabic, 1 mg
expression is up-regulated in differentiating mammary epi- 17b-estradiol in PBS and gum arabic, 1 mg progesterone in gum
arabic and PBS, or both 1 mg 17b-estradiol and 1 mg progesterone.thelial cells independently of changes in proliferation. Inter-
Injections of either PBS or 17b-estradiol, and either gum arabic orestingly, each of these changes in expression appears to oc-
progesterone, were given via separate injections each day for a totalcur coordinately with Brca1 (Rajan et al., 1996).
of 13 ±20 days, at which time mice were sacri®ced for analysis.As a ®rst step toward understanding the developmental
and hormonal regulation of Brca2, we have analyzed the
RNA Preparation and Analysisspatial and temporal pattern of expression of this gene in
the mouse during fetal development, in adult tissues, in RNA was prepared by homogenization of snap-frozen tissue sam-
the mammary gland during postnatal development, and in ples in guanidinium isothiocyanate with a polytron homogenizer,
followed by ultracentrifugation through cesium chloride, as pre-ovariectomized animals treated with steroid hormones. We
viously described (Chirgwin et al., 1979). Poly(A)/ RNA was se-have found that Brca2 is expressed at highest levels in prolif-
lected using oligo(dT) cellulose (Pharmacia). Northern hybridiza-erating cellular compartments, particularly those undergo-
tion analysis was performed as described (Marquis et al., 1995).ing differentiation. Surprisingly, we have found that in mul-
Northern blots containing poly(A)/ RNA derived from human tis-tiple fetal and adult tissues the spatial and temporal pattern
sues (Clontech) were processed according to the manufacturer's
of Brca2 mRNA expression is strikingly similar to that of directions. DNA fragments used as probes included a 1.0-kb region
Brca1, including the mammary gland during postnatal de- of human BRCA1 cDNA corresponding to amino acids 760 to 1099,
velopment. These observations imply that Brca2 is involved the corresponding region of mouse Brca1, nucleotides 281 to 853
in the processes of proliferation and differentiation in the of the human BRCA2 cDNA, or the corresponding region of the
mammary gland and other tissues, and that the expression mouse Brca2 cDNA (GenBank Accession No. U72947).
RNase protection analysis of Brca1 mRNA expression was per-of Brca1 and Brca2 may be regulated by similar pathways
formed as described (Marquis et al., 1995). RNase protection analy-and stimuli in multiple cell types. Interestingly, we have
sis of Brca2 mRNA expression was performed as described for Brca1found that the ratio of mRNA expression in the mammary
using a 240-bp fragment of mouse Brca2 corresponding to aminoglands of adult females relative to adult males is signi®-
acids 127 to 208 of human BRCA2. A 100-bp fragment of mouse b-cantly greater for Brca1 than for Brca2. In addition, we have
actin corresponding to nucleotides 1142±1241 (Genbank Accession
shown that Brca1 and Brca2 expression are differentially No. X03672) was subcloned into the pGEM-T vector (Promega) and
regulated during the development of speci®c endocrine tar- processed as described above as an internal control along with ei-
get tissues, such as the testis during spermatogenesis and ther the Brca2 or Brca1 probes.
the breast during pregnancy. In particular, our studies of
ovariectomized mice treated with combinations 17b-estra- In Situ Hybridization
diol and progesterone demonstrate that Brca1 and Brca2
In situ hybridization was performed as described using a mousemRNA expression in the breast are differentially regulated
Brca2 cDNA corresponding to amino acids 19±208 of human
by sex hormones, raising the possibility that the elevated BRCA2, a mouse Brca1 cDNA corresponding to amino acids
risk of breast cancer in men carrying germline mutations 727±1108 of murine Brca1, or nucleotides 542 to 768 of mouse
in BRCA2 but not BRCA1 may re¯ect this differential regu- p21WAF1/CIP1 cDNA (Marquis et al., 1995). Slides were developed at
lation. 10 days and 4 weeks and analyzed by bright- and dark-®eld micros-
copy using a Leica DMR microscope. Dark-®eld photomicrographs
of sense controls were in all cases taken of sections adjacent to
those used for the antisense photomicrograph. Shutter exposureMATERIALS AND METHODS
times used in photographing sections hybridized to sense controls
were in all cases equal to those used in photographing the antisenseAnimals and Tissues
section.
FVB mice were used in all experiments and were housed under
barrier conditions with a 12-hr light/dark cycle. Mouse embryos RESULTS
were harvested from timed natural matings of FVB mice. Day 0.5
p.c. was de®ned as noon of the day on which a vaginal plug was mRNA Expression of the Murine Homologue of
observed. Adult organs were harvested from 15- to 16-week-old BRCA2
female virgin mice. Tissues used for RNA preparation were snap
A cDNA fragment encoding the region of mouse Brca2frozen on dry ice. Tissues used for in situ hybridization analysis
were embedded in OCT medium and frozen in a dry ice/isopentane corresponding to exons 2±6 of the human gene was isolated
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FIG. 1. Murine and human BRCA2 mRNA transcripts are similar in size and do not cross-hybridize with BRCA1. Northern hybridization
analysis of human BRCA2 expression (A), mouse Brca2 expression (B), human BRCA1 expression (C), mouse Brca1 expression (D), or
human BRCA2 and mouse Brca2 expression (E) in human MCF-7 breast carcinoma cells (lane 1), human primary ®broblasts (lane 2), the
nontransformed mouse mammary epithelial cell line HC11 (lane 3), or the Ha-ras overexpressing mouse breast cancer cell line, AC816
(lane 4). Northern blots contained 6 mg of poly(A)/ RNA from each cell line. The relative migration of RNA molecular size standards is
shown. The position of the major BRCA2 transcript is indicated by an arrow. The positions of minor BRCA2 transcripts are indicated by
arrowheads.
by RT-PCR using murine mammary epithelial cDNA and 70% identity at the amino acid level. The sequence of
mBrca2.1 was subsequently con®rmed by comparison withprimers directed against the 5* end of human BRCA2. Com-
parison of the sequence of the resulting murine cDNA frag- overlapping cDNA and genomic clones. BLAST analysis of
mBrca2.1 identi®ed signi®cant homology only to humanment, designated mBrca2.1, with BRCA2 revealed 78%
identity at the nucleic acid level and 80% similarity and BRCA2. Analysis of a murine genomic clone containing
FIG. 2. Brca2 mRNA expression colocalizes with Brca1 mRNA expression during murine embryonic development. (A) RNase protection
analysis of Brca2, Brca1, and b-actin mRNA expression at Days 6.5, 13.5, and 18.5 of mouse embryonic development. 50 mg of total RNA
from the indicated developmental time points was hybridized to 32P-labeled antisense probes for Brca2 or Brca1. A 32P-labeled antisense
probe for b-actin was included in each reaction as an internal control. (B) In situ hybridization analysis of Brca2 and Brca1 mRNA
expression in Day 13.5 mouse embryos. Bright-®eld and dark-®eld photomicrographs of serial frozen sections from Day 13.5 mouse
embryos hybridized to antisense (a±c) or sense (d±f) 35S-labeled probes for Brca2 (a, b, d, and e) or Brca1 (c and f). (C) Bright-®eld and dark-
®eld photomicrographs of serial frozen sections from sagitally sectioned Day 18.5 mouse embryos hybridized to 35S-labeled antisense or
sense probes for Brca2, Brca1, or p21WAF1/CIP1, as indicated. bf, brown adipose tissue; bl, urinary bladder; bo, bowel; di, diaphragm; fv,
fourth ventricle; hf, hair follicle; ht, heart; li, liver; lu, lung; lv, lateral ventricle of brain; mv, mesencephalic vesicle; md, roof of midbrain;
mg, midgut; oe, olfactory epithelium; po, pons; re, respiratory epithelium; sc, spinal cord; sg, submandibular gland; sk, skin; st, stomach;
tb, tooth bud; th, thymus; to, tongue; vl, ventricular layer of brain.
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FIG. 3. Tissue-speci®c expression of human and mouse Brca2. (A) Expression of BRCA2 and BRCA1 mRNA in human tissues.
Northern hybridization analysis of poly(A)/ RNA isolated from the indicated human tissues (Clontech) with 32P-labeled probes for
either BRCA2 or BRCA1. The relative migration of RNA molecular size markers is shown. The position of a minor BRCA2 mRNA
species is indicated by an arrowhead. (B) Expression of Brca2 and Brca1 mRNA in adult mouse organs. RNase protection analysis
of mRNA isolated from the indicated tissues using 32P-labeled antisense probes for Brca2, Brca1, or b-actin. A tRNA control shows
the position of two nonspeci®c bands present in the Brca1 probe. The position of the protected fragment corresponding to Brca1
mRNA is indicated by an arrow. The 28S ribosomal RNA band is shown from an ethidium bromide-stained gel containing the
same samples.
exons homologous to exons 2±10 of human BRCA2 re- thymus (Couch et al., 1996a; Tavtigian et al., 1996). Exon
11-derived human and mouse BRCA1 probes detected mes-vealed the conservation of intron/exon boundaries (data not
shown). sages approximately 7.8 and 7.5 kb in length in human and
mouse cell lines, respectively (Figs. 1C and 1D). No cross-In order to address whether mBrca2.1 is derived from the
bona ®de murine homologue of BRCA2 and to rule out the hybridization was detected between murine Brca2 and mu-
rine Brca1 under any conditions. Weak cross-hybridizationexistence of cross-hybridization between Brca1 and Brca2
probes, identical Northern blots containing poly(A)/ RNA between murine Brca2.1 and human BRCA2, and between
murine Brca1 and human BRCA1, was detected only atprepared from both human and mouse cell lines were probed
with radiolabeled cDNA fragments derived from corre- lower washing stringencies (data not shown). Taken to-
gether, the sequence homology, genomic structure, mRNAsponding regions of the cDNAs encoding human BRCA2,
murine Brca2, human BRCA1, and murine Brca1 (Fig. 1). size, and similar tissue distribution of expression (see be-
low) strongly suggest that mBrca2.1 is derived from the bonaA cDNA probe encoding exons 2±6 of human BRCA2 de-
tected a message approximately 11±11.5 kb in length in ®de murine homologue of BRCA2.
human but not in murine cell lines (Figs. 1A and 1E). Con-
versely, a murine probe derived from the corresponding re-
Brca2 Is Widely Expressed during Embryogenesisgion detected a message approximately 11 kb in length in
murine, but not human, cells lines (Figs. 1B and 1E). Re- The temporal pattern of Brca2 mRNA expression during
murine embryogenesis was examined by RNase protectionprobing these blots with human BRCA2 probes derived
from either exon 11 or exons 20±24 yielded similar hybrid- analysis. Analysis of steady-state levels of Brca2 mRNA
during embryonic development revealed peak levels ofization patterns (data not shown). A minor mRNA species
1.8 kb in length was detected in both murine and human Brca2 mRNA expression at Day 13.5 of gestation and lower
but detectable levels of expression at Days 6.5 and 18.5samples, in addition to a 2.6-kb minor species detected in
murine samples (Figs. 1E and 3A). An 11- to 12-kb BRCA2 (Fig. 2A). A similar pattern was observed for Brca1 mRNA
expression.transcript has previously been detected in human testis and
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In order to determine the spatial localization of Brca2 centa (data not shown). Northern blots that were stripped
and reprobed with a BRCA1 cDNA probe derived from exonmRNA expression during fetal development, in situ hybrid-
ization was performed on frozen sections of Day 13.5 em- 11 revealed a tissue-speci®c pattern of mRNA expression
for BRCA1 similar to that for BRCA2 (Fig. 3A).bryos using 35S-labeled sense and antisense Brca2 probes
generated from the region corresponding to human exons Analysis of steady-state levels of Brca2 mRNA in tissues
of the adult mouse by RNase protection revealed a tissue-2±6. Brca2 mRNA was widely expressed in Day 13.5 em-
bryos with highest levels of expression observed in the fetal speci®c pattern of expression similar to that of human
BRCA2, with high levels of expression observed in testis andliver, midgut, the ventricular layer of the brain, and the
germinal neuroblastic epithelium of the developing eye (Fig. moderate levels in thymus, spleen, and ovary (Fig. 3B). Lower
but detectable levels of Brca2 expression were observed in the2B and data not shown). This pattern of expression was
similar to that which we previously described for Brca1 breast and other tissues. RNase protection analysis of Brca1
mRNA expression in these same samples revealed a pattern(Marquis et al., 1995). In situ hybridization performed on
adjacent sections of Day 13.5 embryos using antisense and similar to that observed for Brca2 (Fig. 3B).
The localization of Brca2 mRNA expression in adultsense probes for Brca1 con®rmed this similarity (Fig. 2B).
To extend these ®ndings, in situ hybridization was per- tissues, and its potential colocalization with Brca1,
were investigated by in situ hybridization performed onformed on serial sections of Day 18.5 embryos using 35S-
labeled sense and antisense probes generated from Brca2, serial tissue sections using probes for Brca2, Brca1, and
p21WAF1/CIP1 (Fig. 4A). Brca2 mRNA expression in the breastBrca1, or p21WAF1/CIP1 (Fig. 2C). p21WAF1/CIP1 was chosen as
a control since it represents a gene known to be involved was principally restricted to the epithelium (Figs. 4A and
6D). Brca2 expression in the ovary was predominantly follic-in the regulation of proliferation and differentiation in
mammalian cells (Parker et al., 1995). In situ hybridization ular, with the highest levels of mRNA found in granulosa
cells in developing follicles and relatively lower levels inanalysis revealed intense organ-speci®c expression of Brca2
mRNA in the liver, lung, bowel, salivary gland, thymus, stromal cells. Brca2 mRNA expression in the duodenum was
found predominantly in the basal epithelial cell layer locatedtooth bud, brown adipose tissue, skin, olfactory epithelium,
and ventricular layer of the brain. This pattern of expression at the base of the intestinal crypts, areas known to contain
rapidly dividing cell types undergoing differentiation. In thesuggests that Brca2 is expressed during fetal development
in cellular compartments characterized by rapid prolifera- uterus, Brca2 expression was observed at highest levels in
the glandular portions of the endometrium with moderatetion and differentiation. In addition, as observed in Day 13.5
embryos, each of the Day 18.5 fetal tissues displaying high levels of expression observed throughout the stroma. Strik-
ingly, as observed during fetal development, the spatial pat-levels of Brca2 mRNA also exhibited high levels of Brca1
mRNA. In fact, the spatial pattern and relative intensity of tern of Brca2 mRNA expression in the breast, ovary, duode-
num, and uterus was virtually identical to that observed formRNA expression within each organ observed for Brca2
and Brca1 were virtually indistinguishable, with the excep- Brca1. This pattern differed markedly from that observed for
p21WAF1/CIP1, whose expression occurred at highest levels intion of regions of the brain and spinal cord, which exhibited
Brca2 but not Brca1 expression. In contrast, the pattern of terminally differentiated cell types such as the columnar
cells of the gastric and intestinal epithelium found most dis-expression observed for Brca2 and Brca1 differed markedly
with that observed for p21WAF1/CIP1 mRNA (Fig. 2C). tal to the crypts (Fig. 4A and Parker et al., 1995).
The spatial patterns of Brca2 mRNA expression in thep21WAF1/CIP1 exhibited high levels of expression in skeletal
muscle, cartilage, skin, nasal epithelium, and other termi- testis, thymus, prostate, liver, and spleen were also similar
to those previously described for Brca1 (Fig. 4B). In addition,nally differentiated cells, consistent with prior observations
(Parker et al., 1995). in situ hybridization analysis con®rmed the presence of
Brca2, but not Brca1, mRNA expression in the brain of
adult animals, consistent with results obtained from RNase
Brca2 Expression in Adult Tissues Re¯ects Patterns protection analysis (Fig. 3B and 4B). An additional difference
of Proliferation and Differentiation between Brca1 and Brca2 expression in adult tissues was
revealed by in situ hybridization studies of the stomach.The distribution of Brca2 expression was analyzed in hu-
man and adult mouse tissues by Northern hybridization, While both Brca1 and Brca2 expression in the stomach were
found principally in the basal epithelial cell layer at theRNase protection analysis, and in situ hybridization and
was compared with that observed for Brca1. Like Brca1, base of the mucosal epithelium, signi®cant expression of
Brca2, but not Brca1, was also observed in the more differ-the level of Brca2 mRNA expression as detected by these
methods was relatively low. Human BRCA2 cDNA probes entiated epithelial cells migrating towards the tips of the
gastric villi (Fig. 4A). Thus, as observed during fetal develop-detected an mRNA species approximately 11 kb in length
in human testis and thymus on Northern blots containing ment, Brca2 mRNA expression in the adult was found in a
wide variety of tissues, was generally associated with prolif-poly(A)/ RNA derived from a variety of human tissues (Fig.
3A). Longer exposures of autoradiograms revealed detect- erating cellular compartments undergoing differentiation,
and was strikingly similar to that observed for Brca1. De-able levels of expression in spleen, small intestine, and pla-
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FIG. 4. Brca2 is expressed in proliferating cellular compartments in adult tissues (A) Brca2 mRNA expression colocalizes with Brca1
mRNA expression in adult mouse organs. Bright-®eld and dark-®eld (antisense) photomicrographs of in situ hybridization analysis per-
formed on serial frozen sections of the indicated tissues using 35S-labeled antisense probes for Brca2, Brca1, or p21WAF1/CIP1, as indicated.
No signal was detected over background in serial sections hybridized with sense Brca2, Brca1, or p21WAF1/CIP1 probes (data not shown). al,
developing alveoli in mammary gland of pregnant animal; st, stroma; f, developing follicle; gr, granulosa cells; mu, intestinal or gastric
mucosa; ic, intestinal crypts; se, serosa; eg, endometrial glands; lu, lumen of bowel. (B) Localization of Brca2 mRNA expression in
additional tissues of the adult mouse. Bright ®eld and dark ®eld (antisense) photomicrographs of in situ hybridization analysis performed
on frozen sections of the indicated tissues using an 35S-labeled antisense probe for Brca2. No signal was detected over background in serial
sections hybridized with a sense Brca2 probe (data not shown). bm, basement membrane; co, thymic cortex; cp, capsule; ct, connective
tissue; ep, epithelium; me, thymic medulla; se, seminferous tubule; st, stroma.
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FIG. 5. Developmental up-regulation of Brca2, but not Brca1, mRNA expression during spermatogenesis. (A) RNase protection analysis
of Brca2 and Brca1 developmental expression during spermatogenesis. RNase protection analysis of total RNA isolated from the testes
of mice at the indicated ages using antisense probes for Brca2, Brca1, or b-actin. (B) In situ hybridization analysis of Brca2 and Brca1
developmental expression during spermatogenesis. Bright-®eld and dark-®eld photomicrographs of in situ hybridization analysis performed
on serial sections of testis harvested from mice at the indicated ages using antisense probes for Brca2 or Brca1. To facilitate comparison,
all dark-®eld photomicrographs shown were taken using identical shutter exposure times.
spite this similarity, however, the spatial patterns of Brca2 steady-state levels of Brca1 mRNA were essentially con-
stant during this same period of postnatal development. Inand Brca1 expression were distinguishable in some tissues.
situ hybridization analysis of testes harvested from mice
during the ®rst 3 weeks of life con®rmed the up-regulation
Brca2 Expression, but Not Brca1 Expression, Is of Brca2 mRNA as well as the relatively constant level of
Up-Regulated during Spermatogenesis expression of Brca1 mRNA and further suggested that this
up-regulation was global in nature, resulting from increasedThe high levels of Brca2 expression observed in the testis,
steady-state levels of Brca2 mRNA in the majority of cellsthe localization of Brca2 expression in cellular compart-
in the seminiferous tubule rather than from an increase inments involved in proliferation and differentiation, and the
the fraction of expressing cells (Fig. 5B). These results sup-gender-speci®c aspects of the phenotype resulting from
port the hypothesis that Brca2 plays a role in the regulationgermline BRCA2 mutations compared with germline muta-
of proliferation and/or differentiation during spermatogene-
tions in BRCA1 prompted us to examine Brca2 mRNA ex-
sis. The differences observed in developmental expression
pression during spermatogenesis. The analysis of differenti-
patterns between Brca1 and Brca2 during this process may
ation in this system is facilitated by the fact that while
re¯ect underlying differences in the patterns of regulation
in adult mice the various differentiating cell types appear
or functions of these genes, particularly those relevant tosimultaneously, during the ®rst round of spermatogenesis
androgen-responsive tissues.which occurs during the ®rst few weeks of life cell types
characteristic of each of the stages of differentiation appear
synchronously and sequentially as enriched populations Brca2 Expression Is Induced in the Mammary
(Janca et al., 1986; Nebel et al., 1961). Steady-state levels Gland during Puberty and Pregnancy
of Brca2 mRNA in the testis were analyzed by RNase pro-
tection as a function of age from 6 to 27 days following birth RNase protection analysis and in situ hybridization were
used to determine the spatial and temporal pattern of Brca2(Fig. 5A). This analysis revealed that steady-state levels of
Brca2 mRNA progressively rise in the developing testis be- expression during the postnatal development of the mammary
gland (Fig. 6). Throughout the course of mammary gland devel-ginning at about Day 12 of life, peaking by approximately
4 weeks of age, and remaining high in adult life. In contrast, opment, Brca2 mRNA was expressed predominantly in epi-
Copyright q 1997 by Academic Press. All rights of reproduction in any form reserved.
AID DB 8526 / 6x1f$$$$$3 04-08-97 13:50:19 dbas
394 Rajan et al.
thelial cells, with lower but detectable levels of expression al., 1995). Moreover, both Brca1 and Brca2 are expressed at
signi®cantly higher levels in the female breast compared toobserved in the stromal portion of the gland (Figs. 4A and 6D).
This observation is consistent with the fact that germline the male breast, presumably re¯ecting the greater amount
of mammary epithelium present in the adult female (Fig.mutations in BRCA2 predispose carriers to malignant trans-
formation of the mammary epithelium. Brca2 mRNA levels 6D). However, two intriguing differences were noted in the
quantitative patterns of expression of these two genes dur-in the mammary glands of 2- and 5-week-old immature virgin
females were signi®cantly higher than those found in the ing mammary gland development. First the magnitude of
the up-regulation in Brca1 mRNA levels that occurred inmammary glands of 10- and 15-week-old mature virgin fe-
males (Figs. 6A and 6E). This is clearly evident upon normal- the breast during early pregnancy was approximately twice
that observed for Brca2 (Figs. 6B and 6C). Second, quantita-ization of steady-state levels of Brca2 mRNA to those of b-
actin (Fig. 6B), which is required to distinguish genuine regula- tive analysis of steady-state Brca2 and Brca1 mRNA levels
in multiple independent pooled mammary gland samplestory effects from nonspeci®c dilutional effects resulting from
the large-scale accumulation of milk protein mRNAs during corresponding to over 200 age-matched male and female
mice revealed that the ratio of mRNA expression in thelate pregnancy and lactation (Buhler et al., 1993; Gavin and
McMahon, 1992; Marquis et al., 1995). Consistent with the mammary glands of adult females relative to adult males
was signi®cantly greater for Brca1 than for Brca2 (Fig. 6D).higher steady-state levels of Brca2 mRNA observed in the
mammary glands of immature mice by RNase protection, in These observations suggest that androgens and/or ovarian
hormones differentially regulate the expression of Brca1situ hybridization performed on the mammary glands of im-
mature mice revealed higher levels of Brca2 mRNA in termi- and Brca2 at the mRNA level.
nal end buds than in adjacent ducts (Fig. 6E and data not
shown). Terminal end buds are undifferentiated structures Brca2 and Brca1 Expression Are Differentiallywhich are present in the breast primarily during puberty and
Regulated by Ovarian Hormoneswhich contain rapidly proliferating cell types undergoing dif-
ferentiation. In situ hybridization performed on the mammary The observation that Brca2 mRNA levels are up-regu-
lated during pregnancy suggested that the expression of thisglands of adult virgin mice con®rmed the low levels of Brca2
mRNA present in the mammary epithelium of mature mice gene may be modulated directly or indirectly by ovarian
hormones. Moreover, the observation that the up-regulation(Fig. 6E). The decrease in Brca2 mRNA levels observed follow-
ing puberty is consistent with the elevated level of Brca2 of Brca2 mRNA levels during early pregnancy is less
marked than that observed for Brca1, and that the ratio ofexpression found in terminal end buds relative to mature
ducts and parallels the disappearance of these structures at mRNA expression in the mammary glands of female rela-
tive to male mice is signi®cantly greater for Brca1 than forthe completion of ductal morphogenesis. As assayed by RNase
protection, Brca2 mRNA levels in the female breast increased Brca2, suggested that the expression of these two genes may
respond to ovarian hormones in a quantitatively differentsharply early in pregnancy, a period during which alveolar
buds begin the process of rapid proliferation and differentia- manner. In order to test this hypothesis in vivo, the effect
of ovariectomy on Brca1 and Brca2 mRNA expression levelstion to form mature, milk-producing alveoli (Figs. 6A and 6B).
In situ hybridization demonstrated that this up-regulation of was determined. Steady-state levels of Brca1 and Brca2
mRNA were signi®cantly lower in the mammary glandsBrca2 expression occurred preferentially in developing alveoli
as compared with adjacent epithelial ducts (Fig. 6E). Brca2 of ovariectomized mice compared with age-matched intact
animals (Fig. 7A). That this decrease was due at least inexpression declined during the remainder of pregnancy (Days
14 and 20), reaching its nadir during lactation and early post- part to the loss of ovarian hormones was suggested by the
observation that steady-state levels of Brca2 mRNA werelactational regression as assayed by RNase protection and in
situ hybridization (Figs. 6A, 6B, and 6E). Interestingly, RNase restored in ovariectomized mice by treatment with a combi-
nation of 17b-estradiol and progesterone. By comparison,protection analysis revealed that the mammary glands of par-
ous animals which had undergone four weeks of postlacta- the induction of Brca1 mRNA expression by estradiol and
progesterone was signi®cantly greater than that observedtional regression expressed higher levels of Brca2 mRNA than
the mammary glands of age-matched virgin controls (Figs. 6A for Brca2 (Fig. 7A). The relative induction of Brca1 and
Brca2 expression by each of these hormones was investi-and 6B).
The parallel determination of steady-state levels of Brca1 gated in ovariectomized mice (Fig. 7B). Consistent with our
previous observations, as assayed by RNase protectionmRNA in the same samples used to analyze Brca2 expres-
sion during mammary gland development revealed several Brca1 mRNA levels were low in ovariectomized animals
and increased slightly in response to 17b-estradiol alone,interesting points (Figs. 6A and 6C). Like Brca2, Brca1 is
predominantly expressed in the mammary epithelium moderately in response to progesterone alone, and synergis-
tically in response to a combination of these two hormonesthroughout the postnatal development of this organ (Lane
et al., 1995; Marquis et al., 1995). Also like Brca2, Brca1 (Fig. 7B and Marquis et al., 1995). By comparison, the
induction of Brca2 expression in the mammary glands ofmRNA levels are up-regulated during puberty, pregnancy,
and as a result of parity (Figs. 6A and 6C and Marquis et animals treated with a combination of 17b-estradiol and
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FIG. 6. Coordinate expression of Brca2 and Brca1 during postnatal mammary gland development. (A) RNase protection analysis of
mRNA isolated from the mammary glands of mice at the indicated developmental stages using 32P-labeled antisense probes for Brca2,
Brca1, or b-actin. The 28S ribosomal RNA band is shown from an ethidium bromide-stained gel containing the same samples. (B)
Phosphorimager quantitation of Brca2 mRNA expression shown in (A). Brca2 mRNA expression is normalized to b-actin mRNA expression
to correct for dilutional changes in signal intensity resulting from large-scale increases in milk protein mRNA production during late
pregnancy and lactation. The Brca2/actin ratio is de®ned as 1.0 for the 15-week virgin sample. (C) Phosphorimager quantitation of Brca1
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mRNA levels both declined in the mammary epithelium of
ovariectomized relative to sham-operated animals. Treat-
ment of ovariectomized animals with both 17b-estradiol
and progesterone resulted in the synergistic up-regulation
of Brca1 mRNA expression. In contrast, consistent with our
RNase protection results, the up-regulation of Brca2 mRNA
levels in ovariectomized animals treated with a combina-
tion of 17b-estradiol and progesterone was signi®cantly
lower than that observed for Brca1.
DISCUSSION
We have analyzed the spatial and temporal pattern of
Brca2 mRNA expression during fetal development, in adult
tissues, in the mammary gland during postnatal develop-
ment and in ovariectomized animals treated with various
combinations of ovarian hormones. These studies suggest
that Brca2 is expressed during fetal development and in
adult tissues within cellular compartments actively in-
volved in proliferation and differentiation. This hypothesis
is supported by the observation that Brca2 mRNA expres-
sion in the breast is developmentally regulated and is found
at highest levels in terminal end buds during puberty and
differentiating alveoli during pregnancy. Moreover, this pat-
tern of expression is consistent with the genetic identi®ca-
tion of BRCA2 as a tumor suppressor gene and suggests
that this gene may play a role in the regulation of cellular
proliferation and differentiation in the mammary gland and
other tissues.
Coordinate and Differential Regulation of Brca1
and Brca2 Expression
FIG. 6ÐContinued A particularly intriguing ®nding of these studies is the
striking degree to which Brca2 and Brca1 are temporally
and spatially coexpressed at the mRNA level. Brca1 and
Brca2 are expressed at similar relative levels in a similar
set of tissues and in similar cellular compartments withinprogesterone was signi®cantly less marked than that for
Brca1 (Fig. 7B). those tissues. In fact, during fetal development and in multi-
ple adult tissues, including breast, ovary, uterus, and smallThese observations were con®rmed by in situ hybridiza-
tion performed on mammary glands harvested from the intestine, the spatial and temporal patterns of Brca1 and
Brca2 expression are virtually indistinguishable. This simi-same experimental animals (Fig. 7C). Brca2 and Brca1
mRNA expression shown in (A). Brca1 mRNA expression is normalized to b-actin mRNA expression to correct for dilutional changes in
signal intensity. The Brca1/actin ratio is de®ned as 1.0 for the 15-week virgin sample. (D) Phosphorimager quantitation of Brca1 and
Brca2 mRNA expression levels in the mammary glands of age-matched adult male and female mice normalized to actin, and of the ratio
of female:male mRNA expression for each of these genes. Mammary glands from approximately 130 females and 80 males were analyzed
as multiple independently pooled samples. *P  0.005; ³P  0.01. Error bars represent the standard error of the mean. (E) In situ
hybridization analysis of Brca2 mRNA expression during postnatal mammary gland development. Bright-®eld and dark-®eld (antisense)
photomicrographs of sections from mouse mammary glands at the indicated developmental time points hybridized to a Brca2 antisense
probe. No signal was detected over background in serial sections hybridized with a sense Brca2 probe (data not shown). teb, terminal end
bud; st, mammary stroma; d, epithelial duct; al, developing alveoli during pregnancy; lo, casein-secreting lobule during lactation or early
regression.
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FIG. 7. Differential induction of Brca1 and Brca2 mRNA expression in the mammary gland by ovarian hormones. (A) Brca2 expression
is dependent on ovarian hormones. RNase protection analysis of Brca2 and Brca1 mRNA expression in the mammary glands of control
and ovariectomized mice treated with estradiol and progesterone. Control animals (Sham) did not undergo surgery. Ovariectomized mice
received either no hormone (OVX) or a combination of 17b-estradiol and progesterone (OVX / E2 / P) for 13 days prior to sacri®ce. A
32P-labeled antisense probe for b-actin was included in each reaction as an internal control. (B) Brca2 mRNA is induced by estradiol and
progesterone to a lesser extent than Brca1. RNase protection analysis of Brca2 and Brca1 mRNA expression in the mammary glands of
ovariectomized mice treated with varying combinations of ovarian hormones. Ovariectomized mice received either no hormone (OVX),
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larity is particularly evident during postnatal mammary associated with an increased risk of both male and female
breast cancer, whereas the increased breast cancer risk associ-gland development, as each of these putative tumor suppres-
sor genes is up-regulated during puberty and pregnancy and ated with germline BRCA1 mutations is restricted to females.
These ®ndings raise the possibility that the gender-speci®cas a result of parity. A potential basis for this similarity is
provided by the observation that Brca1 and Brca2 expres- differences in breast cancer risk associated with germline mu-
tations in BRCA1 versus BRCA2 re¯ect the differential regu-sion are coordinately up-regulated in proliferating and dif-
ferentiating mammary epithelial cells in vitro (Rajan et al., lation of these genes by sex hormones.
1996). These ®ndings suggest that the mRNA expression of
these two breast cancer susceptibility genes may be regu-
Regulation of Brca1 and Brca2 Expression inlated by similar pathways and stimuli in multiple cell types.
Proliferating CellsGiven this striking similarity and the fact that mammary
epithelial cells are similarly predisposed to transformation A central feature of the in vivo pattern of Brca1 and
Brca2 expression is that each of these putative tumor sup-by inherited mutations in either BRCA1 or BRCA2, it is
tempting to speculate that BRCA1 and BRCA2 may have pressor genes is expressed at maximal levels in rapidly
proliferating cells. This feature is consistent with in vitrooverlapping functions or may even act in concert. Neverthe-
less, the fact that germline mutations in BRCA2 predispose observations that Brca1 and Brca2 mRNA expression are
each up-regulated in rapidly proliferating cells, are down-carriers to increased risks of breast cancer despite the pres-
ence of presumably wild-type copies of BRCA1, and vice- regulated in response to serum deprivation, and are ex-
pressed in a cell cycle-dependent manner, peaking at theversa, suggests that the functions of these two genes are not
entirely redundant. This conclusion is supported by the fact G1/S boundary (Chen et al., 1996; Gudas et al., 1996;
Rajan et al., 1996; Vaughn et al., 1996a,b). Formally, thesethat germline mutations in BRCA1 and BRCA2 result in
distinct phenotypes with respect to the incidence of ovarian observations are consistent with a model in which Brca1
and Brca2 exert a positive effect on proliferation. Such acancer, male breast cancer, and pancreatic cancer.
Given the remarkable similarities in the expression pro®les model would be compatible with studies demonstrating
that mouse embryos bearing homozygous targeted muta-of Brca1 and Brca2, differences in the expression pattern of
these two genes may be informative. Our studies demonstrate tions in Brca1 exhibit a decrease in cellular proliferation
(Hakem et al., 1996; Liu et al., 1996). Of particular inter-that Brca1 and Brca2 expression are differentially regulated
in the breast by ovarian hormones. Speci®cally, Brca1 expres- est is the observation that p21WAF1/CIP1 expression is up-
regulated in cells bearing homozygous deletions insion is induced in the breast to a signi®cantly greater extent
than Brca2 both during pregnancy and following estradiol and Brca1, suggesting that Brca1 may negatively regulate
p21WAF1/CIP1 expression (Hakem et al., 1996). This hy-progesterone treatment of ovariectomized mice. Conversely,
Brca2 mRNA levels are markedly up-regulated in the testis pothesis would be consistent with our observation that
Brca1 and p21WAF1/CIP1 are expressed in several fetal tis-during the ®rst 4 weeks of life, whereas Brca1 mRNA levels
remain essentially unchanged. Taken together, these results sues in a mutually exclusive pattern. Nevertheless, it is
dif®cult to reconcile a model in which Brca1 and Brca2indicate that Brca1 and Brca2 mRNA expression are differen-
tially regulated by sex hormones. In this regard, it is interest- positively regulate cellular proliferation with the genetic
evidence that BRCA1 and BRCA2 are tumor suppressoring to note that mRNA expression in the mammary glands
of female mice relative to male mice is signi®cantly greater genes and with the observations that overexpression of
BRCA1 inhibits proliferation while reduction in BRCA1for Brca1 than for Brca2. Presumably, this may re¯ect, at least
in part, the more pronounced effect of ovarian hormones on expression promotes proliferation (Holt et al., 1996; Rao
et al., 1996; Thompson et al., 1995). Moreover, analysisBrca1 expression. The ®nding that Brca1 expression levels in
the breast are markedly greater in females relative to males, of a third Brca1 knockout model suggests that mouse em-
bryos bearing homozygous targeted mutations in Brca1whereas Brca2 expression levels are more comparable, is par-
ticularly intriguing given that germline BRCA2 mutations are may exhibit an increase, rather than a decrease, in prolif-
17b-estradiol alone (OVX / E2), progesterone alone (OVX / P), or a combination of 17b-estradiol and progesterone (OVX / E2 / P) for
20 days prior to sacri®ce. A 32P-labeled antisense probe for b-actin was included in each reaction as an internal control. (C) In situ
hybridization analysis of Brca2 and Brca1 mRNA expression in mammary glands from ovariectomized mice treated with ovarian hormones.
Bright-®eld and dark-®eld (antisense) photomicrographs of in situ hybridization analysis performed using 35S-labeled antisense probes for
Brca2 or Brca1 on frozen sections of mammary glands harvested from ovariectomized mice that treated with either no hormone (OVX),
17b-estradiol alone (OVX / E2), progesterone alone (OVX / P), or a combination of 17b-estradiol and progesterone (OVX / E2 / P).
Control animals (Sham) did not undergo surgery. Sections shown for Brca2 and Brca1 antisense probes for each experimental treatment
were taken from the same mammary gland of the same animal. To facilitate comparison, all dark-®eld photomicrographs shown were
taken using identical shutter exposure times. No signal was detected over background in serial sections hybridized with sense Brca2 or
Brca1 probes (data not shown). d, epithelial duct; st, stroma; al, developing alveolus.
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eration in certain cell types (Gowen et al., 1996). As such, nogenesis, as well as provide insight into their role in the
developmental regulation of proliferation and differentia-whether BRCA1 is a positive or negative regulator of pro-
liferation in adult tissues remains unclear. One possibil- tion in mammalian cells.
ity is that the functions of BRCA1 in embryonic tissues
may differ from those in adult tissues. Regardless, the
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